Discovery of biomarker evidence in Castleman Disease exemplifies the value of personalized medicine in rare diseases
- The Castleman Disease Collaborative Network presented new research
supported by Medidata at 60th Annual Meeting of the
American Society of Hematology
- Application of Medidata Rave Omics reveals new patient subgroups that can accelerate diagnosis and treatment
- Medidata data analysis in collaboration with the Castleman Disease Collaborative Network advances personalized medicine for life-threatening disorder
Idiopathic Multicentric Castleman Disease (iMCD) is a rare, difficult to diagnose, life-threatening disorder.1 The CDCN advances research programs to develop better diagnostic methods, identify patients that will respond to approved therapy and find new drug targets to develop new therapies.
“iMCD stumped my doctors, and they didn’t think I would survive. My
mission today is to bring new treatment options and hope to Castleman
Disease patients and other poorly understood rare diseases,” said Dr.
Medidata Rave Omics enabled the discovery of novel biomarkers for Castleman disease. With unparalleled industry expertise, Medidata data scientists collaborated with the Castleman Disease Collaborative Network to make the following insights:
- Six new patient subsets reflecting either distinct subtypes or proteomic disease states
- Evidence of proteomic predictors of anti-interleukin-6 treatment response
- Etiological insights into the poorly understood rare disease and toward new potential drug targets
“Medidata's analytics empower researchers to make new discoveries for
all patients, including those with rare diseases,” said
Medidata Rave Omics streamlines omic data capture, linking and analysis inside the clinical study process. To learn more about Medidata, visit mdsol.com.
1 Fajgenbaum D, Ruth J, Kelleher D, Rubenstein A. Lancet Haematology. 2016;3:150-152
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
About Castleman Disease Collaborative Network (CDCN)
CDCN is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. The CDCN’s innovative approach first involved building a global community of over 400 physicians and researchers, assembling a scientific advisory board of 28 experts from eight countries, and supporting and engaging patients in research prioritization. Then, the CDCN crowdsourced among the global community to identify gaps in medical knowledge and determine high priority research projects. In parallel, the CDCN connects and supports thousands of CD patients around the world. Now, the CDCN recruits top researchers to conduct studies, and works with patients, loved ones, and the public to raise funding to enable these studies. More information is available at: www.CDCN.org
Betsy Frank, +1 917-522-4620
Erik Snider, +1 646-362-2997